Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study-Reference-Cited by-同舟云学术

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

Published:2014-07-03 Issue:9 Volume:261 Page:1794-1802
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Arnold Douglas L.,Gold Ralf,Kappos Ludwig,Bar-Or Amit,Giovannoni Gavin,Selmaj Krzysztof,Yang Minhua,Zhang Ray,Stephan Monica,Sheikh Sarah I.,Dawson Katherine T.

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

http://link.springer.com/article/10.1007/s00415-014-7412-x/fulltext.html

Reference26 articles.

1. Miller DH, Altmann DR, Chard DT (2012) Advances in imaging to support the development of novel therapies for multiple sclerosis. Clin Pharmacol Ther 91(4):621–634. doi: 10.1038/clpt.2011.349

2. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56(4):548–555. doi: 10.1002/ana.20224

3. Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CR, Weiner HL, Gasperini C, Filippi M (1999) Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 353(9157):964–969 (pii):S0140673698030530

4. Filippi M, Rocca MA, De Stefano N, Enzinger C, Fisher E, Horsfield MA, Inglese M, Pelletier D, Comi G (2011) Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol 68(12):1514–1520. doi: 10.1001/archneurol.2011.914

5. Tam RC, Traboulsee A, Riddehough A, Sheikhzadeh F, Li DK (2011) The impact of intensity variations in T1-hypointense lesions on clinical correlations in multiple sclerosis. Mult Scler 17(8):949–957. doi: 10.1177/1352458511402113

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of fingolimod on focal and diffuse damage in patients with relapsing–remitting multiple sclerosis – The “EVOLUTION” study;Journal of Neurology;2024-07-29

2. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-01-04

3. Prevalence of 2-year “No evidence of disease activity” (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study;Multiple Sclerosis and Related Disorders;2023-11

4. Real-world persistence to first-line DMTs in relapsing-remitting multiple sclerosis;Multiple Sclerosis and Related Disorders;2023-10

5. Metabolomics Profile of the Secretome of Space-Flown Oligodendrocytes;Cells;2023-09-11